Rita Nogueiras-Álvarez

Dr. Rita Nogueiras-Álvarez

Hospital Universitario Galdakao-Usansolo, Galdakao, Spain
orcid
PhD. Physician. Clinical pharmacologist

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
RNRita Nogueiras-Álvarez
Rita Nogueiras-Álvarez
With the trend towards promoting personalised medicine (PM), the application of pharmacogenetics and pharmacogenomics (PGx) is of growing importance. For the purposes of clinical trials, the inclusion of PGx is an additional tool that should be considered for improving our knowledge about the effectiveness and safety of new drugs. A search of available clinical trials containing pharmacogenetic and PGx information was conducted on ClinicalTrials.gov. The results show there has been an increase in the number of trials containing PGx information since the 2000 s, with particular relevance in the areas of Oncology (28.43%) and Mental Health (10.66%). Most of the clinical trials focus on treatment as their primary purpose. In those clinical trials entries where the specific genes considered for study are detailed, the most frequently explored genes are CYP2D6 (especially in Mental Health and Pain), CYP2C9 (in Hematology), CYP2C19 (in Cardiology and Mental Health) and ABCB1 and CYP3A5 (particularly prominent in Transplantation and Cardiology), among others. Researchers and clinicans should be trained in pharmacogenetics and PGx in order to be able to make a proper interpretation of this data, contributing to better prescribing decisions and an improvement in patients’ care, which would lead to the performance of PM.

8 December 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RNRita Nogueiras-Álvarez
Rita Nogueiras-Álvarez
VMVictor Manuel Mora-Cuesta
Victor Manuel Mora-Cuesta
JCJosé Manuel Cifrián-Martínez
José Manuel Cifrián-Martínez
MCMARIA ANGELES DE COS
MARIA ANGELES DE COS
MGMaría del Mar García-Sáiz
María del Mar García-Sáiz
Patients undergoing lung transplantation (LTx) need administration of immunosuppressive therapy following the procedure to prevent graft rejection. However, these drugs are not exempt from potential risks. The development of cardiovascular risk factors and impaired renal function in the post-transplantation period are conditions that may be favoured by the use of calcineurin inhibitor (CNI) drugs which could have repercussions on the quality of life and the post-transplantation evolution. To evaluate the cardiovascular and renal toxicity following the administration of CNI as maintenance immunosuppression in lung transplant recipients (LTRs) we reviewed a total number of 165 patients undergoing LTx between 01/01/2015 and 08/12/2018. They were divided into two groups according to the CNI drug administrated: cyclosporine (CsA-group) with 11 patients or tacrolimus (Tac-group), with 154 patients. We evaluated the de novo occurrence of arterial hypertension (HTN), diabetes mellitus (DM), hyperlipidemia and impaired renal function after initiation of CNI administration. In addition to that, the time until each of these events was assessed. A higher rate for developing HTN (p < 0.001) and impaired renal function (p = 0.047) was observed within the CsA-group. The new onset of hyperlipidemia was similar between both CNI groups and de novo appearance of DM was only documented in those LTRs receiving tacrolimus. In this LTRs retrospective study, it was observed that having ≥ 4 tacrolimus trough levels above the upper limit of the proposed interval for each specific post-LTx period was associated with an increased risk for developing renal impairment. No other statistically significant association was found between supratherapeutic CNIs blood levels and the evaluated toxicities.

30 July 2024 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
RNRita Nogueiras-Álvarez
Rita Nogueiras-Álvarez
IFInés Pérez Francisco
Inés Pérez Francisco

12 June 2025 in Clinical Transplantation
Verified
Journal Article
Closed access
RNRita Nogueiras-Álvarez
Rita Nogueiras-Álvarez
MGMaría del Mar García‐Saiz
María del Mar García‐Saiz

17 January 2022 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
Andrej BelančićAndrej Belančić
Andrej Belančić
CSCarla Sans-Pola
Carla Sans-Pola
EJEmilie Jouanjus
Emilie Jouanjus
PAPau Alcubilla
Pau Alcubilla
AAAna Lucía Arellano
Ana Lucía Arellano
TGthe EACPT Young Clinical Pharmacologists Working Group
the EACPT Young Clinical Pharmacologists Working Group